Phase II Trial On The Effects Of Silexan In Patients With Neurasthenia, Post-traumatic Stress Disorder Or Somatization Disorder
Notes for this study:
|Number of Subjects
||18-29, 30-44, 45-64
80mg of Silexan for 6 weeks in persons with anxiety related disorders (neurasthenia, PTSD, and somatization disorder) was associated with a reduction of anxiety and restlessness like symptoms (associated with neurasthenia) relative to baseline in more than half of the sample.